Tag: MDVN

Medivation, Inc and Interexon Corporation may see bullish sentiments today

MDVN – Medivation, Inc., offers medical therapies to treat serious diseases like Cancer.

MDVN – Medivation, Inc.

Fundamentals Previously closed at 38.75
Day’s high 38.89
Day’s low 35.55
P/E ratio 26.07
EPS 1.47

 

Analysts opinion MDVN has a forward PE of 19.09, a profit margin of 25.95%. It is held mostly by institutional investors (95.5%). The stock slumped yesterday by 6% as it attracted the attention of Presidential candidate Bernie Sanders and a few other influential congressmen. Medivation manufactures “Xtandi”, a prostate cancer drug which has been highly priced in the U.S compared to other countries. The lawmakers would like to reduce the prices in U.S as well. MDVN’s partner, Astellas responded to that most patients with private insurance pay a minimum out of their pockets and the manufacturer provides Xtandi free of cost for many eligible uninsured or underinsured patients. However, analysts have a consensus “Buy” opinion for the stock with a price target of $47.
Sentiments This year, being the election year in the U.S., the political environment tends to affect the stock price movements. MDVN’s sentiments have been bearish but investors expect the prices to rise once the focus shifts from the company. Investors may see this dip as an opportunity to buy the stock.
Social Media Pulse The stock has 100% higher chatter than usual.

Continue Reading…